Big Reversal: Actavis Now Plans China Expansion, Post-Allergan

In January of this year, Paul Bisaro, Chairman and CEO of Actavis, declared the company would exit China: the regulatory system was too unpredictable and the profit margins too small, he said. In the ten months since then, Actavis has become a different company because of two giant acquisitions: first Forest Labs and more recently Allergan, a $66 billion transaction. It also has a new CEO: Brent Saunders, who had been CEO of Forest Labs. Actavis officials told Bloomberg that the Allergan takeover would involve job losses for some people, but China would now become a growth area. More details.... Stock Symbol: (NYSE: ACT) Share this with colleagues: // //